Antihypertensives and COVID-19: Literature review

Thais Cristina Loyola da  Silva; Pedro Vilar de Oliveira  Villarim; Alyne Barreto Mesquita de  Goés; Vitória Ribeiro Dantas  Marinho; Natália Marcelino  Araújo; André Luiz Costa e  Silva; Amália Cinthia Meneses  Rêgo; Irami  Araújo-Filho

doi:10.33448/rsd-v10i6.15977

Autores/as

Thais Cristina Loyola da Silva Liga Norte Riograndense Contra o Câncer, Natal-RN, Brazil. https://orcid.org/0000-0003-1605-9923
Pedro Vilar de Oliveira Villarim Liga Norte Riograndense Contra o Câncer, Natal-RN, Brazil. https://orcid.org/0000-0002-9504-8589
Alyne Barreto Mesquita de Goés Liga Norte Riograndense Contra o Câncer, Natal-RN, Brazil. https://orcid.org/0000-0001-5187-6174
Vitória Ribeiro Dantas Marinho Liga Norte Riograndense Contra o Câncer, Natal-RN, Brazil. https://orcid.org/0000-0002-8514-1560
Natália Marcelino Araújo Liga Norte Riograndense Contra o Câncer, Natal-RN, Brazil. https://orcid.org/0000-0003-3143-6299
André Luiz Costa e Silva Liga Norte Riograndense Contra o Câncer, Natal-RN, Brazil. https://orcid.org/0000-0001-7255-3833
Amália Cinthia Meneses Rêgo Potiguar University https://orcid.org/0000-0002-0575-3752
Irami Araújo-Filho Universidade Federal do Rio Grande do Norte https://orcid.org/0000-0003-2471-7447

DOI:

https://doi.org/10.33448/rsd-v10i6.15977

Palabras clave:

Agentes Antihipertensivos; Inhibidores de la Enzima Convertidora de Angiotensina; Hipertensión; SARS-CoV-2; COVID-19.

Resumen

Los pacientes hipertensos con COVID-19 son susceptibles a complicaciones de la enfermedad, por lo que este estudio tuvo como objetivo analizar la acción de los fármacos que actúan sobre la Angiotensina (TA) en presencia de COVID-19 en comparación con otros antihipertensivos, así como identificar la los principales. evidencia sobre el tema presentado hasta ahora. Se trata de una revisión integradora de la literatura que contiene 34 artículos seleccionados según los criterios de inclusión, entre enero / 2020 a febrero / 2021, en las bases de datos PubMed, Embase, Scopus y Web of Science. Los resultados no muestran una relación causal entre el aumento de la infección por COVID-19 y el uso de inhibidores del RAAS, sino un posible efecto protector de estos frente a la manifestación grave de la enfermedad debido a la inhibición de las enfermedades proinflamatorias de AT II. Así, aproximadamente la cuarta parte de los estudios defendieron la continuidad del uso y el factor de protección de los bloqueadores de RAAS en detrimento de las otras clases de fármacos antihipertensivos que no modulan el RAAS. Se constató, entonces, que se debe mantener el tratamiento antihipertensivo, ya que no empeora el pronóstico ante la infección por Sars-CoV-2. Sin embargo, los estudios son principalmente observacionales y, por lo tanto, no pueden establecer relaciones causales sólidas. Por esta razón, se necesitan ensayos controlados aleatorios sólidos para comprender mejor este tema.

Citas

Abajo, F. J., Rodríguez-Martín, S., Lerma, V., Mejía-Abril, G., Aguilar, M., & García-Luque, A., et al. (2020). Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 395(10238), 1705-1714. https://doi.org/10.1016/S0140-6736(20)31030-8.

Alnajjar, R., Mostafa, A., Kandeil, A., & Al-Karmalawy, A. A. (2020). Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease. Heliyon. 6(12), e05641. https://doi.org/10.1016/j.heliyon.2020.e05641.

Antwi-Amoabeng, D., Beutler, B. D., Moody, A. E., Kanji, Z., Gullapalli, N., & Rowan, C. J. (2020). Management of hypertension in COVID-19. World J Cardiol. 12(5), 228-230. https://doi.org/10.4330/wjc.v12.i5.228.

Cadegiani, F. A., Goren, A., & Wambier, C. G. (2020). Spironolactone can provide protection against SARS-CoV-2: androgen targets, angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin-aldosterone system (RAAS). J Med Hypotheses. 143, 110112. https://doi.org/10.1016 / j.mehy.2020.110112.

Cheng, H., Wang, Y., & Wang, L-Q. (2020). Organ‐protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID‐19. J Med Virol. 92, 726 - 730. https://doi.org/10.1002/jmv.25785.

Dantas, T. C. de A. ., Gomes, A. C. A. ., Lima, I. P. C. ., Lucas , B. B. ., Aguiar, M. R. de ., Cavalcanti, T. C. de H. ., Pinheiro, F. I. ., Rêgo, A. C. M. ., & Araújo-Filho, I. (2021). Corticosteroid therapy in patients with severe COVID-19. Research, Society and Development, 10(1), e58910112114. https://doi.org/10.33448/rsd-v10i1.12114.

Delpino, M. V., & Quarleri, J. (2020) SARS-CoV-2 Pathogenesis: Imbalance in the Renin-Angiotensin System Favors Lung Fibrosis. Front Cell Infect Microbiol. 10(340). doi: https://doi.org/10.3389/fcimb.2020.00340.

Fang, L., Karakiulakis, G., & Roth, M. (2020). Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 8(4), e21. https://doi.org/10.1016/S2213-2600(20)30116-8.

Gao, C., Cai, Y., Zhang, K., Zhou, L., & Zhang, Y., et al. (2020). Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J. 41(22), 2058-2066. https://doi.org/10.1093/eurheartj/ehaa433.

Goes, A. B., Cardoso, B. B., Tavares, F. A., Monte, R. R., et al. (2020). COVID-19 and Nervous System: Under Estimated Clinical and Prognostic Aspects. International Journal of Neurology Neurotherapy, 7(100), 1-7. https://doi.org/10.23937/2378-3001/1410100.

Grasselli, G., Greco, M., Zanella, A., Albano, G., Antonelli, M., & Bellani, G., et al. (2020). COVID-19 Lombardy ICU Network. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern Med. 180(10), 1345-1355. https://doi.org/10.1001/jamainternmed.2020.3539.

Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., & He, J., et al. (2020). Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 382, 1708-20. https://doi.org/10.1056/NEJMoa2002032.

Gurwitz, D. (2020). Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics. Drug Dev Res. 81, 537-540. https://doi.org/10.1002/ddr.21656.

Hypertension ECo. (2020). Position Statement of the ESC Council on Hypertension on ACEInhibitors and Angiotensin Receptor Blockers [internet]. [acesso em 2021 Fev 20]. Disponível em: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-councilon-hypertension-on-ace-inhibitors-and-ang.

Jakhmola, S., Indari, O., Baral, B., Kashyap, D., Varshney, N., Das A., Chatterjee, S., & Jha, H. C. (2020) Comorbidity Assessment Is Essential During COVID-19 Treatment. Front Physiol. 11(984). https://doi.org/10.3389/fphys.2020.00984.

Kim, J., Kim, D. W., Kim, K. I., Kim, H. B., Kim, J. H., & Lee, Y. G., et al. (2020) Korean Society of Hypertension. Compliance of Antihypertensive Medication and Risk of Coronavirus Disease 2019: a Cohort Study Using Big Data from the Korean National Health Insurance Service. J Korean Med Sci. 35(25), e232. https://doi.org/10.3346/jkms.2020.35.e232.

Libby, P., & Lüscher, T. (2020). COVID-19 is, in the end, an endothelial disease. Eur Heart J. 41(32), 3038-3044. https://doi.org/10.1093/eurheartj/ehaa623.

Malhotra, A., Hepokoski, M., McCowen, K. C. & Y-J Shyy J. (2020). ACE2, Metformin, and COVID-19. iScience. 23(9), 101425. https://doi.org/10.1016/j.isci.2020.101425.

Mancia, G., Rea, F., Ludergnani, M., Apolone, G., & Corrao, G. (2020). Blockers of the renin-angiotensin-aldosterone system and the risk of Covid-19. N Engl J Med. 382(25), 2431-2440. https://doi.org/10.1056 / NEJMoa2006923.

Marin, G. H. (2020). Facts and reflections on COVID-19 and anti-hypertensives drugs. Drug Discov Ther. 14(2), 105-106. https://doi.org/10.5582/ddt.2020.01017.

Meng, J., Xiao, G., Zhang, J., He, X., & Ou, M., et al. (2020). Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 9(1), 757-760. https://doi.org/10.1080/22221751.2020.1746200.

Monte, R. R., Tavares, F. A., Cardoso, B. B., Goes, A. B., et al. (2020). Covid-19 Pandemic and Health Professionals: Practical Approaches. International Journal of Critical Care Emergency Medicine, 6(108), 1-9. https://doi.org/10.23937/2474-3674/1510108.

Nejat, R., & Sadr, A. S. (2020). Are losartan and imatinib effective against SARS-CoV2 pathogenesis? A pathophysiologic-based in silico study. In Silico Pharmacol. 9(1), 1. https://doi.org/10.1007/s40203-020-00058-7.

Organização Pan-Americana de Saúde; Organização Mundial da Saúde [homepage na internet]. (2021). Folha informativa COVID-19 - Escritório da OPAS e da OMS no Brasil. [acesso 2021 Fev 09]. Disponível em: https://www.paho.org/pt/covid19.

Ramírez-Sagredo, A., Ramírez-Reyes, A., Ocaranza, M. P., Chiong, M., Riquelme, J. A., & Jalil, J. E., et al. (2020). Anti hypertensive agents in patients with COVID-19. Rev Chil Cardiol. 39(1), 66-74. http://dx.doi.org/10.4067/S0718-85602020000100066.

Reynolds, H. R., Adhikari, S., Pulgarin, C., Troxel, A. B., Iturrate, E., & Johnson, S. B, et al. (2020). Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med. 382(25), 2441-2448. https://doi.org/10.1056/NEJMoa2008975.

Rothlin, R. P., Vetulli, H. M., Duarte, M., & Pelorosso, F. G. (2020). Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19. Drug Dev Res. 81(7), 768-770. https://doi.org/10.1002/ddr.21679.

Ruilope, L. M., Tamargo, J., & Ruiz-Hurtado, G. (2020). Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs. Eur Heart J. 41(22), 2067–2069. https: //doi.org/10.1093/eurheartj/ehaa487.

Salazar, M., Barochiner, J., Espeche, W., & Ennis, I. (2020). COVID-19, hipertensión y enfermedad cardiovascular [COVID-19 and its relationship with hypertension and cardiovascular disease]. Hipertens Riesgo Vasc. 37(4), 176-180. https://doi.org/10.1016/j.hipert.2020.06.003.

Sardu, C., Maggi, P., Messina, V., Iuliano, P., Sardu, A., & Iovinella, V., et al. (2020). Could Anti-Hypertensive Drug Therapy Affect the Clinical Prognosis of Hypertensive Patients With COVID-19 Infection? Data From Centers of Southern Italy. J Am Heart Assoc. 9(17), e016948. https://doi.org/10.1161/JAHA.120.016948.

Semenzato, L., Botton, J., Drouin, J., Baricault, B., Vabre, C., & Cuenot, F., et al. (2021). Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients. Hypertension. 77(3), 833-842. https://doi.org/10.1161/HYPERTENSIONAHA.120.16314.

Shibata, S., Arima, H., Asayama, K., Hoshide, S., Ichihara, A., & Ishimitsu, T., et al. (2020). Hypertension and related illnesses in the COVID-19 era: a report by the Japanese Hypertension Society Task Force on COVID-19. Hypertens Res. 43(1), 1028–1046. https://doi.org/10.1038/s41440-020-0515-0.

Singh, A. K., Gupta, R., & Misra, A. (2020). Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr. 14(4), 283-287. https://doi.org/10.1016/j.dsx.2020.03.016.

Solaimanzadeh, I. (2020). Nifedipina e amlodipina estão associadas a mortalidade melhorada e risco reduzido de intubação e ventilação mecânica em pacientes idosos hospitalizados por COVID-19. Cureus. 12(5), e8069. https://doi.org/10.7759/cureus.8069.

Trifirò, G., Crisafulli, S., Andò, G., Racagni, G., & Drago, F. (2020). Italian Society of Pharmacology. Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)? Drug Saf. 43(6), 507-509. https://doi.org/10.1007/s40264-020-00935-2.

Trump, S., Lukassen, S., Anker, M. S., Chua, R. L., Liebig, J., & Thürmann L., et al. (2020) Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. Nat Biotechnol. https://doi.org/10.1038/s41587-020-00796-1.

Vila-Corcoles, A., Satue-Gracia, E., Ochoa-Gondar, O., Torrente-Fraga, C., Gomez-Bertomeu, F., & Vila-Rovira, A., et al. (2020). Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia, Spain. J Clin Hypertens (Greenwich). 22(8), 1379-1388. https://doi.org/10.1111/jch.13948.

Antihipertensivos y COVID-19: Revisión de la literatura

Autores/as

DOI:

Palabras clave:

Resumen

Citas

Descargas

Publicado

Cómo citar

Número

Sección

Licencia

JOURNAL METRICS

Idioma

Enviar un artículo